CarboplatinDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsAntimetabolites, AntineoplasticPaclitaxelDrug Administration SchedulePancreatic NeoplasmsCisplatinLung NeoplasmsTreatment OutcomeCarcinoma, Non-Small-Cell LungAntineoplastic AgentsInfusions, IntravenousOvarian NeoplasmsDeoxycytidine KinaseThrombocytopeniaPlatinumOrganoplatinum CompoundsMaximum Tolerated DoseCombined Modality TherapyEtoposideDisease-Free SurvivalNeutropeniaArea Under CurveIfosfamideDose-Response Relationship, DrugVinblastineTaxoidsSurvival RateLeukopeniaNeoplasm StagingAdenocarcinomaDrug Resistance, NeoplasmDrug SynergismNeoplasmsBiliary Tract NeoplasmsHematologic DiseasesCell Line, TumorFallopian Tube NeoplasmsGuanineUrologic NeoplasmsNauseaGlutamatesEquilibrative Nucleoside Transporter 1Retinal NeoplasmsFluorouracilNeoplasm MetastasisPeritoneal NeoplasmsThiotepaNeoplasm Recurrence, LocalAntineoplastic Agents, PhytogenicTopotecanSalvage TherapyRetinoblastomaRadiation-Sensitizing AgentsCarcinomaSurvival AnalysisXenograft Model Antitumor AssaysDrug EvaluationDisease ProgressionDoxorubicinAntibodies, Monoclonal, HumanizedCarcinoma, Small CellVomitingCarcinoma, Transitional CellCamptothecinCarcinoma, Pancreatic DuctalTime FactorsDrug Screening Assays, AntitumorAmifostineKaplan-Meier EstimateNeoplasms, Unknown PrimaryMice, NudeRemission InductionLead RadioisotopesCyclophosphamideGerminomaChemotherapy, AdjuvantRibonucleoside Diphosphate ReductaseUrinary Bladder NeoplasmsFeasibility StudiesTesticular NeoplasmsAdministration, OralSeminomaQuinazolinesDrug HypersensitivityApoptosisPlatinum CompoundsIsocoumarinsCA-19-9 AntigenDrug InteractionsDose FractionationPrognosisNeoplasms, Germ Cell and EmbryonalEpirubicinCarcinoma, Large CellSurvivalPleural NeoplasmsAntibodies, MonoclonalNeoadjuvant Therapy